Iconic Therapeutics

Industry: Ophthamology

Biopharma company licensing a novel recominant protein called hI-con1, which binds tissue factor, thus triggering cells that selectively destroy pathologic nerovascular blood vessels. 

Company website: Iconic Therapeutics

Back to companies